BioPharma Credit PLC (BPCR.L)
USD 0.89
(0.91%)
USD 0.89
(0.91%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | 123.18 Million | 184.27 Million | 96.43 Million | 58.07 Million | 131.52 Million | 67.13 Million |
| Net Income | 108.45 Million | 182.31 Million | 84.95 Million | 89.13 Million | 122.32 Million | 70.14 Million |
| Depreciation & Amortization | - | - | - | - | - | - |
| Deferred income taxes | - | - | - | - | - | - |
| Stock-based compensation | - | - | - | - | - | - |
| Change in working capital | -9.22 Million | 7.88 Million | -12.29 Million | 156 Thousand | 17.74 Million | -6.29 Million |
| Other non-cash items | 23.95 Million | -5.91 Million | 23.77 Million | -31.22 Million | -8.55 Million | 3.28 Million |
| Investing Cash Flow | -1.65 Million | 48.19 Million | -94.82 Million | -47.47 Million | -100.29 Million | -436.98 Million |
| Investments in PPE | - | - | - | - | - | - |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | -36.65 Million | -100 Million | -187.14 Million | -225.73 Million | -508.5 Million | -658.78 Million |
| Sales/Maturities of investments | 35 Million | 148.19 Million | 92.32 Million | 178.26 Million | 408.21 Million | 221.8 Million |
| Other Investing Activities | -1.65 Million | 48.19 Million | -94.82 Million | -47.47 Million | -100.29 Million | -436.98 Million |
| Financing Cash Flow | -106.99 Million | -206.62 Million | -100.15 Million | -113.95 Million | -98.14 Million | 382.63 Million |
| Debt repayment | - | - | - | - | - | - |
| Dividends payments | -89.77 Million | -156.53 Million | -100.15 Million | -113.89 Million | -98.61 Million | -74.04 Million |
| Common Stock Repurchased | -17.22 Million | -50.08 Million | - | -60 Thousand | - | - |
| Common Stock Issuance | - | - | - | - | 467 Thousand | 468.78 Million |
| Other Financing Activities | - | -110.88 Million | -3.98 Million | -17.78 Million | -1.97 Million | -12.1 Million |
| Accounts receivables | -479 Thousand | -9.82 Million | -9.8 Million | 15.99 Million | 5.76 Million | -16.93 Million |
| Accounts payables | -8.74 Million | 17.71 Million | -2.49 Million | -15.84 Million | 11.98 Million | 10.63 Million |
| Inventory | - | - | - | - | - | - |
| Other working capital | -8.74 Million | 17.71 Million | -2.49 Million | -15.84 Million | 11.98 Million | - |
| Cash at beginning of period | 120.52 Million | 94.7 Million | 193.26 Million | 296.63 Million | 363.57 Million | 350.82 Million |
| Cash at end of period | 135.05 Million | 120.52 Million | 94.7 Million | 193.26 Million | 296.63 Million | 363.57 Million |
| Capital Expenditure | - | - | - | - | - | - |
| Effect of forex changes on cash | -7000.00 | -29 Thousand | -18 Thousand | -12 Thousand | -12 Thousand | -38 Thousand |
| Net cash flow / Change in cash | 14.52 Million | 25.81 Million | -98.56 Million | -103.36 Million | -66.93 Million | 12.75 Million |
| Free Cash Flow | 123.18 Million | 184.27 Million | 96.43 Million | 58.07 Million | 131.52 Million | 67.13 Million |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 FY | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | 35.91 Million | 35.91 Million | 18.76 Million | 108.45 Million | 18.76 Million | 35.46 Million |
| Depreciation & Amortization | - | - | - | - | - | - |
| Deferred income taxes | - | - | - | - | - | - |
| Stock-based compensation | - | - | - | - | - | - |
| Change in working capital | -8.34 Million | -8.34 Million | 9.63 Million | -9.22 Million | 9.63 Million | -9.87 Million |
| Other non-cash items | -3.75 Million | -3.75 Million | 17.99 Million | 23.95 Million | 17.99 Million | -10.39 Million |
| Investing Cash Flow | 19.53 Million | 19.53 Million | 500.00 | -1.65 Million | 500.00 | -828.5 Thousand |
| Investments in PPE | - | - | - | - | - | - |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | - | - | 1000.00 | -36.65 Million | - | - |
| Sales/Maturities of investments | 39.07 Million | - | - | 35 Million | - | - |
| Other Investing Activities | 19.53 Million | 19.53 Million | 500.00 | -1.65 Million | 500.00 | -828.5 Thousand |
| Financing Cash Flow | -92.31 Million | -92.31 Million | -12.79 Million | -106.99 Million | -12.79 Million | -40.69 Million |
| Debt repayment | - | - | - | - | - | - |
| Dividends payments | -53.99 Million | -53.99 Million | -11.39 Million | -89.77 Million | -11.39 Million | -33.48 Million |
| Common Stock Repurchased | -38.31 Million | -38.31 Million | -1.39 Million | -17.22 Million | -1.39 Million | -7.21 Million |
| Common Stock Issuance | - | - | - | - | - | - |
| Other Financing Activities | - | - | -1.00 | - | -1.00 | -17.62 Million |
| Accounts receivables | -8.34 Million | -8.34 Million | 9.63 Million | -479 Thousand | 9.63 Million | -9.87 Million |
| Accounts payables | -12.33 Million | - | 11.86 Million | -8.74 Million | - | - |
| Inventory | - | - | - | - | - | - |
| Other working capital | - | - | - | -8.74 Million | - | - |
| Cash at beginning of period | 135.05 Million | - | 67.87 Million | 120.52 Million | - | - |
| Cash at end of period | 37.14 Million | -48.95 Million | 33.58 Million | 135.05 Million | 33.58 Million | -26.32 Million |
| Capital Expenditure | - | - | - | - | - | - |
| Effect of forex changes on cash | - | - | -3500.00 | -7000.00 | -3500.00 | - |
| Net cash flow / Change in cash | -97.9 Million | -48.95 Million | -34.28 Million | 14.52 Million | 33.58 Million | -26.32 Million |
| Free Cash Flow | 23.82 Million | 23.82 Million | 46.38 Million | 123.18 Million | 46.38 Million | 15.2 Million |
COTQF
RNC
600691
0I14
AZM
GLENMARK